ecancermedicalscience

Clinical Study

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

12 Oct 2016
Pan Pantziarka, Gauthier Bouche, Vidula Sukhatme, Lydie Meheus, Ilse Rooman, Vikas P Sukhatme

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response. Based on this evidence the case is made for further clinical investigation of the anticancer effects of PRO, particularly in combination with other agents. A number of trials are on-going, in different treatment settings for various cancers.

Related Articles

Manas Dubey, Partha Sarathi Roy, Ankur Bhattacharyya, Kakoli Medhi, Rajdeep Bose, Munlima Hazarika, Pompi Daimari Buragohain, Zaveri Mohinta, Anupam Sarma
Joseph Daniels, Letlhogonolo Ernity Mosadi, Andrew Yaw Nyantakyi, Edwina Ayaaba Ayabilah, Judith Naa Odey Tackie, Kofi Adesi Kyei
Astghik Voskanyan, Lusine Harutyunyan, Arusyak Ivanyan, Alisa Movsisyan, Nerses Ghahramanyan, Lusine Sahakyan, Shushan Hovsepyan, Samvel Danielyan, Hayk Grigoryan, Gevorg Tamamyan
Adu Bukola Gift, Michael Joseph Otorkpa, Oluwatobi O. Olayode, Ebubechukwu David Joseph, Ademola Abdulhakeem, Efuetlateh John Paul Nchonganyi, Feziechi Chikelundu Anele, Akolade Akeem Habib, Fodop Samuel Ghislain Junior, Oluwanifemi O. Akintoye, Omoregbee Benjamin
Dario Alvaro Rueda, Cecilia Schweitzer, Di Nisio Lorena, María Laura Piccoletti, Nicolas Torressi, Víctor Acevedo, Silvia Ferrandini